Scholarlink

Background <p>Severe fever with thrombocytopenia syndrome (SFTS) is a tick-borne viral disease with a mortality rate of 10–30%; however, effective vaccines and therapies for this disease have not yet been developed. Understanding the long-term immune response of recovered individuals is critical for vaccine development and treatment. In this study, we conducted an epidemiological investigation of antibody and memory B cell trends in individuals with SFTS.</p> Methods <p>Peripheral blood mononuclear cells (PBMCs) and plasma were collected from 16 survivors of SFTS and five healthy controls. SFTS virus (SFTSV)-specific humoral immune responses were assessed using enzyme-linked immunosorbent assay (ELISA), biolayer interferometry (BLI), neutralization assays, and flow cytometry.</p> Results <p>SFTSV Gn-specific IgG was detected in plasma samples from all patients using ELISA and BLI. All patient plasma samples also presented neutralizing activity against SFTSV infection, and the IC₅₀ values were correlated with ELISA OD values (<i>ρ</i> = 0.700, <i>P</i> = 0.003 and BLI signals (<i>ρ</i> = 0.818, <i>P</i> = 0.0002). Neutralizing antibodies and SFTSV Gn-specific memory B cells were detected in samples from patients up to 6.7&#xa0;years post-infection.</p> Conclusion <p>SFTSV-specific humoral immunity, including neutralizing antibodies and memory B cells, can persist in the majority of recovered patients, including those as late as 6.7&#xa0;years post-infection. This information will be useful for the development of vaccines and antiviral therapies using antibodies against SFTS.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Sustained humoral immunity in the patients recovered from severe fever with thrombocytopenia syndrome

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月30日

查看全文
  • Ryotaro Kubo,
  • Rokusuke Yoshikawa,
  • Yuji Fujii,
  • Takumi Kawasaki,
  • Takahiro Takazono,
  • Koichi Izumikawa,
  • Koya Ariyoshi,
  • Hiroshi Mukae,
  • Jiro Yasuda

摘要

Background

Severe fever with thrombocytopenia syndrome (SFTS) is a tick-borne viral disease with a mortality rate of 10–30%; however, effective vaccines and therapies for this disease have not yet been developed. Understanding the long-term immune response of recovered individuals is critical for vaccine development and treatment. In this study, we conducted an epidemiological investigation of antibody and memory B cell trends in individuals with SFTS.

Methods

Peripheral blood mononuclear cells (PBMCs) and plasma were collected from 16 survivors of SFTS and five healthy controls. SFTS virus (SFTSV)-specific humoral immune responses were assessed using enzyme-linked immunosorbent assay (ELISA), biolayer interferometry (BLI), neutralization assays, and flow cytometry.

Results

SFTSV Gn-specific IgG was detected in plasma samples from all patients using ELISA and BLI. All patient plasma samples also presented neutralizing activity against SFTSV infection, and the IC₅₀ values were correlated with ELISA OD values (ρ = 0.700, P = 0.003 and BLI signals (ρ = 0.818, P = 0.0002). Neutralizing antibodies and SFTSV Gn-specific memory B cells were detected in samples from patients up to 6.7 years post-infection.

Conclusion

SFTSV-specific humoral immunity, including neutralizing antibodies and memory B cells, can persist in the majority of recovered patients, including those as late as 6.7 years post-infection. This information will be useful for the development of vaccines and antiviral therapies using antibodies against SFTS.